David P. Salmon

Active 1982–2025

174
Papers
51,826
Citations
103
h-index
170
i10-index

Citations

Citations per year for David P. Salmon1983: 2 citations1984: 1 citations1986: 4 citations1987: 4 citations1988: 21 citations1989: 43 citations1990: 37 citations1991: 61 citations1992: 94 citations1993: 112 citations1994: 144 citations1995: 204 citations1996: 253 citations1997: 208 citations1998: 245 citations1999: 240 citations2000: 274 citations2001: 241 citations2002: 284 citations2003: 312 citations2004: 282 citations2005: 294 citations2006: 362 citations2007: 319 citations2008: 350 citations2009: 359 citations2010: 299 citations2011: 364 citations2012: 385 citations2013: 389 citations2014: 395 citations2015: 392 citations2016: 412 citations2017: 458 citations2018: 451 citations2019: 1,597 citations2020: 1,686 citations2021: 1,694 citations2022: 1,386 citations2023: 993 citations2024: 1,655 citations2025: 796 citations2026: 28 citations1985: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,981 citing papers, 30.3% of this breakdownUnited Kingdom: 2,275 citing papers, 9.9% of this breakdownChina: 1,331 citing papers, 5.8% of this breakdownItaly: 1,083 citing papers, 4.7% of this breakdownGermany: 1,047 citing papers, 4.5% of this breakdownCanada: 995 citing papers, 4.3% of this breakdownAustralia: 832 citing papers, 3.6% of this breakdownSweden: 808 citing papers, 3.5% of this breakdownNetherlands: 801 citing papers, 3.5% of this breakdownFrance: 738 citing papers, 3.2% of this breakdownSpain: 725 citing papers, 3.1% of this breakdownJapan: 596 citing papers, 2.6% of this breakdown
0%30.3%Other 21%

Fields

  • Medicine68%
  • Neuroscience19.4%
  • Biochemistry, Genetics and Molecular Biology5.4%
  • Psychology2.4%
  • Computer Science1%
  • Health Professions0.9%
  • Other2.9%

Topics

  • Dementia and Cognitive Impairment Research14.7%
  • Alzheimer's disease research and treatments13.3%
  • Parkinson's Disease Mechanisms and Treatments4.5%
  • Functional Brain Connectivity Studies2.9%
  • Neuroscience and Neuropharmacology Research2.2%
  • Amyotrophic Lateral Sclerosis Research2.1%
  • Other60.3%

Coauthors

All papers

Open in search
  1. Diagnosis and management of dementia with Lewy bodies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Álex Iranzo, Kejal Kantarci, Daniel Kaufer, Walter A. Kukull, Virginia M.‐Y. Lee, James B. Leverenz, Simon J.G. Lewis, Carol F. Lippa, Angela Lunde, Mario Masellis, Eliezer Masliah, Pamela J. McLean, Brit Mollenhauer, Thomas J. Montine, Emilio Moreno, Etsuro Mori, Melissa E. Murray, John T. O’Brien, Sotoshi Orimo, Ronald B. Postuma, Shankar Ramaswamy, Owen A. Ross, David P. Salmon, Andrew Singleton, Angela Taylor, Alan Thomas, Pietro Tiraboschi, Jon B. Toledo, John Q. Trojanowski, Debby W. Tsuang, Zuzana Walker, Masahito Yamada, Kenji Kosaka - Neurology 2017 cited by 4,446

  2. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sandra E. Black, Marsel Mesulam, Sandra Weıntraub, Brad C. Dickerson, Janine Diehl‐Schmid, Florence Pasquier, Vincent Deramecourt, Florence Lebert, Yolande A.L. Pijnenburg, Tiffany W. Chow, Facundo Manes, Jordan Grafman, Stefano F. Cappa, Morris Freedman, Murray Grossman, Bruce L. Miller - Brain 2011 cited by 5,270

  3. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

    Authors: , , , , , , , - Annals of Neurology 1991 cited by 4,411

  4. Research criteria for the diagnosis of prodromal dementia with Lewy bodies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , for the prodromal DLB Diagnostic Study Group - Neurology 2020 cited by 777

  5. The Preclinical Alzheimer Cognitive Composite

    Authors: , , , , , , , - JAMA Neurology 2014 cited by 868

  6. Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS)

    Authors: , , , , , , , , , , , , , , , , , , - Alzheimer Disease & Associated Disorders 2017 cited by 674

  7. Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates

    Authors: , , , , , , , , , , , - Journal of Alzheimer s Disease 2014 cited by 755

  8. A Chinese version of the mini-mental state examination; Impact of illiteracy in a Shanghai dementia survey

    Authors: , , , , , , , , - Journal of Clinical Epidemiology 1988 cited by 1,022

  9. Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change

    Authors: , , , , , , , , , , - Acta Neuropathologica 2022 cited by 227

  10. The Alzheimer's Disease Centers' Uniform Data Set (UDS)

    Authors: , , , , , , , , , , , , , , - Alzheimer Disease & Associated Disorders 2009 cited by 911

  11. Quantification of Five Neuropsychological Approaches to Defining Mild Cognitive Impairment

    Authors: , , , , , , - American Journal of Geriatric Psychiatry 2009 cited by 825

  12. Alzheimer’s Disease: Past, Present, and Future

    Authors: , , - Journal of the International Neuropsychological Society 2017 cited by 632

  13. The A4 Study: Stopping AD Before Symptoms Begin?

    Authors: , , , , , , - Science Translational Medicine 2014 cited by 771

  14. The prevalence of dementia and Alzheimer's disease in Shanghai, China: Impact of age, gender, and education

    Authors: , , , , , , , , , , , - Annals of Neurology 1990 cited by 1,079

  15. The Neuropsychological Profile of Alzheimer Disease

    Authors: , , - Cold Spring Harbor Perspectives in Medicine 2012 cited by 565

  16. NPTX2 and cognitive dysfunction in Alzheimer’s Disease

    Authors: , , , , , , , , , , , , , , , , , , , - eLife 2017 cited by 327

  17. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Neurology 1996 cited by 3,973

  18. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

    Authors: , , , , , , , , , , , , , , , , , - Nature Medicine 2005 cited by 1,046

  19. A phase1 study of stereotactic gene delivery of AAV2‐NGF for Alzheimer's disease

    Authors: , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2014 cited by 223

  20. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , José Brás, Sotoshi Orimo, Mario Masellis, Alan Thomas, Álex Iranzo, Kejal Kantarci, John T. O’Brien, Omar M. A. El‐Agnaf, Bradley F. Boeve, James B. Leverenz, Jon B. Toledo, John E. Duda, Dag Aarsland, David J. Burn, Dennis W. Dickson, Hiroshige Fujishiro, John‐Paul Taylor, F. Blanc, Melissa E. Murray, Brit Mollenhauer, David P. Salmon, Laura Bonanni, Ronald B. Postuma, Emilio Moreno, Virginia M.‐Y. Lee, Debby W. Tsuang, Neill R. Graff‐Radford, Tanis J. Ferman, Douglas Galasko, Patrik Brundin, Simon J.G. Lewis, Zuzana Walker, Ian G. McKeith - 2017 cited by 379

  21. Subjective Cognitive Complaints Contribute to Misdiagnosis of Mild Cognitive Impairment

    Authors: , , , , - Journal of the International Neuropsychological Society 2014 cited by 245

  22. Early versus late MCI: Improved MCI staging using a neuropsychological approach

    Authors: , , , , , , , , , , - Alzheimer s & Dementia 2019 cited by 148

  23. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease

    Authors: , , , , , , , , , , , - Alzheimer s & Dementia Translational Research & Clinical Interventions 2019 cited by 148

  24. Susceptibility of the conventional criteria for mild cognitive impairment to false‐positive diagnostic errors

    Authors: , , , , , , , , , , , - Alzheimer s & Dementia 2014 cited by 254